Cellceutix Corporation (CTIX)


Other OTC - Other OTC Delayed Price. Currency in USD
1.35-0.02 (-1.53%)
At close: 3:59 PM EDT
People also watch:
NVIVNNVCONCSAVXLCUR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.34
Prev Close1.37
Bid0.00 x
Ask0.00 x
Day's Range1.33 - 1.37
52wk Range0.94 - 2.05
1y Target EstN/A
Market Cap166.49M
P/E Ratio (ttm)-12.61
Beta1.68
Volume131,981
Avg Vol (3m)148,896
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals10 days ago

    With new president and focus on big investors, Cellceutix aims for the Nasdaq

    A year after a scathing attack by an anonymous short seller thwarted plans to jump to the Nasdaq, Beverly biotech Cellceutix is hoping a new president with a big pharma background will jumpstart its transformation from a company that’s been mostly ignored by big investors into one that’s traded on the Nasdaq and has institutional shareholders. In June, Cellceutix (CTIX), which employs 14 people, named Arthur Bertolino as its first president and chief medical officer. In an interview last week at the company’s headquarters, CEO Leo Ehrlich called Bertolino — a former Novartis (NVS) and Pfizer (PFE) executive — “the new face of the company,” saying he’ll head up efforts to forge partnerships on its drugs.

  • Marketwired24 days ago

    Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data

    Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide topline ...

  • Marketwiredlast month

    Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis

    Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional......